개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2007.1
- 수록면
- 78 - 89 (12page)
이용수
초록· 키워드
오류제보하기
Hepatitis B virus (HBV) reactivation is the frequent complication after cytotoxic chemotherapy in HBsAg-positive non-Hodgkin's lymphoma (NHL) patients. Pre-chemotherapy viral load may be a risk factor and HBeAg-positive status is associated with increased viral load. The aim of this study was to investigate the long-term treatment outcome of lamivudine in preventing HBV reactivation and its associated morbidity according to HBeAg status. Twenty-four adult HBsAg-positive NHL patients were taken 100mg of lamivudine daily before the initiation of chemotherapy. The median duration of lamivudine therapy was 11.5 months (range: 1-54 months) and the median number of chemotherapy cycles was 6 (range: 1-16 cycles). The steroid containing chemotherapy regimens were used in 18 patients (75%), and the anti-CD20 monoclonal antibody containing chemotherapy regimen was used in 6 patients (25%). Four patients received autologous peripheral blood stem cell transplantation without resultant HBV reactivation. Hepatitis related to HBV reactivation was developed in 1 patient among 14 HBeAg-positive patients and no one among 10 HBeAg-negative. One patient developed HBV reactivation after lamivudine withdrawal, and 4 patients developed the YMDD (tyrosine-methionine-aspartate-aspartate) mutation during lamivudine therapy. There were no statistical differences in HBV reactivation rate during chemotherapy according to the HBeAg status. Our results demonstrate that lamivudine should be considered preemptively before the chemotherapy for all HBsAg-positive NHL patients to prevent HBV reactivation, regardless of pre-chemotherapy HBeAg status. Finally, compared with the chronic hepatitis B patients, similar rate of HBV reactivation after lamivudine withdrawal and development of YMDD mutation was observed in NHL patients.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
[학
Andre F / 2000 / Hepatitis B epidemiology in Asia,the Middle East and Africa 18 : S20 ~ S22
Cheng AL / 2003 / Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV- carriers w
Hoofnagle JH / 1982 / Reactivation of chronic hepatitis B virus infection by cancer chemotherapy 96 : 447 ~ 9
Idilman R / 2005 / Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy 55 : 828 ~ 831
Andre F / 2000 / Hepatitis B epidemiology in Asia,the Middle East and Africa 18 : S20 ~ S22
Cheng AL / 2003 / Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV- carriers w
Hoofnagle JH / 1982 / Reactivation of chronic hepatitis B virus infection by cancer chemotherapy 96 : 447 ~ 9
Idilman R / 2005 / Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy 55 : 828 ~ 831
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Hepatic Failure Caused by Reactivation of YMDD Mutants Occurring during Preemptive Lamivudine Therapy
Gut and Liver
2010 .01
-
A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single- center experience
Clinical and Molecular Hepatology
2013 .01
-
만성 B형 바이러스성 간염환자에서 lamivudine 52주 투여의 치료효과에 대한 연구
The journal of applied pharmacology : the official journal of the Korean Society of Applied Pharmacology
2001 .01
-
Lamivudine Therapy for Korean Children with Chronic Hepatitis B
Yonsei Medical Journal
2007 .01
-
예방적 lamivudine 투여로 성공적인 동종골수이식술을 시행한 HBV 양성 중증 재생불량빈혈 환자 1예
대한내과학회지
2004 .01
-
High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients
Annals of Surgical Treatment and Research
2014 .05
-
라미부딘 투약 후 혈청 HBeAg 소실의 인자로서 투약 후 HBV DNA치
Clinical and Molecular Hepatology
2007 .01
-
만성 B형간질환 환자의 라미부딘 내성 예측인자
Clinical and Molecular Hepatology
2007 .01
-
Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy
Cancer Research and Treatment
2008 .01
-
소아 만성 B형 간염의 관리와 치료
Clinical and Experimental Pediatrics
2007 .01
-
라미부딘 치료에 내성을 보인 만성 B형간염 환자에서 라미부딘 투여 중단 후 임상경과
Clinical and Molecular Hepatology
2005 .01
-
HBeAg 음성 만성 B형 간염 소아청소년 환자에서 라미부딘의 적절 치료 기간 결정을 위한 장기 치료 경험
Pediatric Gastroenterology, Hepatology & Nutrition
2009 .01
-
Result Patterns and Characteristics of HBeAg and HBV DNA in Patients with Chronic Hepatitis B
Laboratory Medicine Online
2019 .01
-
만성 B형 간질환에서 라미부딘 초치료 후의 재발 양상과 재치료 효과
Clinical and Molecular Hepatology
2003 .01
-
만성 B형 간염에서 라미부딘의 치료반응 예측 인자로서 치료 전 ALT치와 조직학적 간염 활성도
Clinical and Molecular Hepatology
2004 .01
-
악성 림프종 환자에서 항암화학요법 후 발생하는 B형 간염의 재활성화
대한내과학회지
2013 .01
-
Is it necessary to delay antiviral therapy for 3.6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
Clinical and Molecular Hepatology
2014 .01
-
A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier
Clinical and Molecular Hepatology
2012 .01
-
Reactivation of Chronic Hepatitis B
한국간담췌외과학회 학술대회지
2014 .04
-
만성 B형 간질환에서 간염 B virus 표식자 발현에 따른 DNA의 검출
영남의대학술지
1997 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0